← Back to Clinical Trials
Recruiting NCT07046546

NCT07046546 Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07046546
Status Recruiting
Phase
Sponsor Royal Berkshire NHS Foundation Trust
Condition Thyroid Nodule (Benign)
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2025-09-29
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Thyroid artery embolization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2025-09-29 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Not all patients are suitable however for these treatments, some lumps are too large, or the patients are not fit enough for surgery. Thyroid artery embolization (TAE) is a new minimally invasive technique (smaller incisions / cuts and shorter recovery time) performed under light sedation. It is used by other European Thyroid Centres, but it hasn't been used in the UK. Embolization means arteries supplying the thyroid gland are blocked by injecting small occlusive particles, like very fine grains of sand that can get stuck in small spaces, preventing blood from passing through. Blocking the thyroid arteries causes the gland to shrink. This provides symptom relief or controls an overactive gland. We aim to undertake a TAE pilot study to explore the safety of TAE in a UK patient population. We are planning to recruit 10 eligible patients. We will also collect additional data (for example on pain, effectiveness, cost and health related quality of life) to inform a future larger trial comparing TAE to other treatment options.

Eligibility Criteria

Inclusion Criteria: * The participant may enter the study if ALL of the following apply: * Adults over 18 years of age willing and able to give informed consent. * Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease). * Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre * TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound. * FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule. * No enlarged / suspicious neck lymphadenopathy on ultrasound. * Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and / or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options. * Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours. Exclusion Criteria: * The participant may enter the study if ALL of the following apply: * Adults over 18 years of age willing and able to give informed consent. * Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease). * Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre * TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound. * FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule. * No enlarged / suspicious neck lymphadenopathy on ultrasound. * Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and / or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options. * Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.

Contact & Investigator

Central Contact

Farhan Ahmad

✉ farhan.ahmad@royalberkshire.nhs.uk

📞 +441183227936

Frequently Asked Questions

Who can join the NCT07046546 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Nodule (Benign). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07046546 currently recruiting?

Yes, NCT07046546 is actively recruiting participants. Contact the research team at farhan.ahmad@royalberkshire.nhs.uk for enrollment information.

Where is the NCT07046546 trial being conducted?

This trial is being conducted at Reading, United Kingdom.

Who is sponsoring the NCT07046546 clinical trial?

NCT07046546 is sponsored by Royal Berkshire NHS Foundation Trust. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology